Cosmo Pharmaceuticals announces RedHill’s Approval of Compassionate Use of Opaganib for the treatment of COVID-19 in Italy
Cosmo Pharmaceuticals N.V. today announced that its participated company RedHill Biopharma – with Cosmo’s support – has obtained approval by the Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (the Italian National Institute for Infectious Diseases) for the immediate compassionate use of its proprietary investigational drug Opaganib (Yeliva®, ABC294640) to treat patients with confirmed coronavirus (COVID-19) infection with life-threatening clinical conditions.